Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7567166rdf:typepubmed:Citationlld:pubmed
pubmed-article:7567166lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:7567166lifeskim:mentionsumls-concept:C0024314lld:lifeskim
pubmed-article:7567166lifeskim:mentionsumls-concept:C0175630lld:lifeskim
pubmed-article:7567166lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7567166lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:7567166pubmed:issue1lld:pubmed
pubmed-article:7567166pubmed:dateCreated1995-10-20lld:pubmed
pubmed-article:7567166pubmed:abstractTextThe immunophenotypes (IF) on peripheral lymphocytes of 24 B-CLL in different stage, 2 PLL and 14 leukemic B-non Hodgkin lymphomas were investigated. As regard to B-CLL and PLL, the results are similar to those reported so far. In stage A and B of B-CLL the IF appear less variable than in advanced stages where a decrease of CD21+ and an increase of both CD25+ and CD38+ lymphocytes were observed. In the lymphocytic, small cleaved cell lymphomas and splenic lymphomas, the peripheral IF correspond to the theoretical ones of respective lymphoma tissues. On the contrary they disagree in three cases of large cells, mixed small and cleaved cell, immunoblastic lymphomas. These features are discussed.lld:pubmed
pubmed-article:7567166pubmed:languageitalld:pubmed
pubmed-article:7567166pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567166pubmed:citationSubsetIMlld:pubmed
pubmed-article:7567166pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7567166pubmed:statusMEDLINElld:pubmed
pubmed-article:7567166pubmed:monthFeblld:pubmed
pubmed-article:7567166pubmed:issn0031-2983lld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:GrossoEElld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:MessinaMMlld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:MorelliCClld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:BüchiGGlld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:AutinoRRlld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:TermineGGlld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:OrlassinoRRlld:pubmed
pubmed-article:7567166pubmed:authorpubmed-author:GirottoMMlld:pubmed
pubmed-article:7567166pubmed:issnTypePrintlld:pubmed
pubmed-article:7567166pubmed:volume87lld:pubmed
pubmed-article:7567166pubmed:ownerNLMlld:pubmed
pubmed-article:7567166pubmed:authorsCompleteYlld:pubmed
pubmed-article:7567166pubmed:pagination50-5lld:pubmed
pubmed-article:7567166pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:meshHeadingpubmed-meshheading:7567166-...lld:pubmed
pubmed-article:7567166pubmed:year1995lld:pubmed
pubmed-article:7567166pubmed:articleTitle[Clinical usefulness of the immunophenotypic study of circulating lymphocytes in leukemic lymphoproliferative diseases].lld:pubmed
pubmed-article:7567166pubmed:affiliationDipartimento di Oncologia, Ospedale Civile di Ivrea, Torino.lld:pubmed
pubmed-article:7567166pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7567166pubmed:publicationTypeEnglish Abstractlld:pubmed